Regeneron Q2 deliveries of COVID-19 treatment came to 1.25 mln or $2.59 bln in sales

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply